Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Direct-acting antiviral therapy for chronic hepatitis C genotype 1 in Denmark
2015-001956-31Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in hepatitis C virus infection comparing Viekira Pak + Dasabuvir + ribavirin with Harvoni + ribavirin (2 arms). Primary endpoint: Frequency of side effects. Started Jun 2015; status: completed.
02
Drugs
Viekira Pakdasabuvirledipasvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2015-001956-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001956-31.